# Definitive Contract #75F40126C00087

Firm-Fixed Price Contract with University of Connecticut for Oligonucleotide Immunogenicity Research

**Buyer:** Food and Drug Administration

**Award Amount:** $1,173,033.00
**Ceiling:** $2,432,643.00

**Awarded:** September 30, 2026
**Period of Performance:** Sep 30, 2026 - Sep 29, 2027

**Identifier:** 75F40126C00087
**NAICS:** 541714

This award represents a definitive contract granted to the University of Connecticut, a reputable academic institution known for advanced biomedical research. The contract involves a firm-fixed price agreement over a multi-year term to investigate the immunogenicity of oligonucleotides, specifically assessing the effects of diastereomers and synthesis-related impurities. The research is significant for the Food and Drug Administration (FDA) as it aims to enhance the understanding of oligonucleotide therapies, potentially improving drug safety and efficacy. The scope of work includes detailed scientific studies on molecular characteristics influencing immune responses. The award was competitively procured, reflecting its importance in advancing pharmaceutical science. Performance is based in Storrs Mansfield, Connecticut, with a potential extension extending the project timeline to allow further in-depth analysis. This contract underscores the FDA’s commitment to supporting critical research that informs regulatory standards and public health.

### Description

FDA BAA FY26C1CP13 3-YEAR FIRM-FIXED PRICE (FFP) CONTRACT FOR INVESTIGATING THE IMPACT OF DIASTEREOMERS AND SYNTHESIS-RELATED IMPURITIES ON THE IMMUNOGENICITY OF OLIGONUCLEOTIDES.

[View original record](https://www.usaspending.gov/award/CONT_AWD_75F40126C00087_7524_-NONE-_-NONE-)